Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 9:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2977–3000 of 33,183 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo Clear all

Conditions: Stage IV Small Cell Lung Cancer
Interventions: OMP-59R5, Etoposide, Placebo, Cisplatin or Carboplatin; Drug
Lead sponsor: OncoMed Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 35
States / cities: Rogers, Arkansas • Los Angeles, California • Denver, Colorado + 29 more

Conditions: Lumbar Spine Surgery
Interventions: Vitamin C, Placebo; Dietary Supplement
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 45 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Acute Pain
Interventions: Oxymorphone immediate release; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 21
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more

Conditions: End Stage Renal Disease, Thrombosis
Interventions: AB002 Dose 1, AB002 Dose 2, placebo; Drug
Lead sponsor: Aronora, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Interventions: Bocidelpar, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Irritable Bowel Syndrome
Interventions: asimadoline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Friedreich Ataxia
Interventions: Nomlabofusp, Placebo; Drug
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chevy Chase, Maryland

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: ADVAIR DISKUS™ 250/50mcg, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 249 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 24
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more

Conditions: Kidney Cancer
Interventions: girentuximab, placebo; Biological · Other
Lead sponsor: Heidelberg Pharma AG; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 864 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 39
States / cities: Anchorage, Alaska • Los Angeles, California • San Francisco, California + 34 more

Conditions: Cardiac Repolarization, Healthy Volunteers
Interventions: Balinatunfib, Moxifloxacin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: Joint Disease, Pain, Acute, Pain, Chronic
Interventions: Cymbalta, Placebo; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 25 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pelvic Pain Syndrome
Interventions: 20 mg baclofen vaginal suppository daily per vagina, Placebo; Drug
Lead sponsor: University of Louisville; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Osteopenia, Osteoporosis
Interventions: Soy isoflavones, Extract tablets; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2003
U.S. locations: 2
States / cities: Davis, California • Ames, Iowa

Conditions: Characteristics That Modify the Response to Cholecalciferol Treatment
Interventions: Vitamin D3, Placebo; Dietary Supplement · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 5
States / cities: Los Angeles, California • Evanston, Illinois • Baltimore, Maryland + 2 more

Conditions: Ankylosing Spondylitis, Axial Spondyloarthritis, Psoriatic Spondylitis, Spondylitis Secondary to Inflammatory Bowel Disease, Axial Spondyloarthopathy
Interventions: Terbinafine Tablets, Laboratory Testing; Drug · Diagnostic Test
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetic Ulcer
Interventions: Topical wound oxygen therapy, Topical wound oxygen Placebo; Device
Lead sponsor: AOTI Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Cryptosporidiosis, HIV Infections
Interventions: Nitazoxanide; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1998
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Diabetes
Interventions: Nutralin; Dietary Supplement
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: ACL Injury
Interventions: Neuromuscular Training; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 19 Years · Female only
Enrollment: 593 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Hypercholesterolemia
Interventions: secoisolariciresinol diglucoside-containing extract of flaxseed; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 40 Years to 65 Years
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Eustachian Tube Dysfunction
Interventions: Fluticasone Propionate 93 MCG/1 ACTUATION Nasal Spray, Placebo Nasal Spray; Drug · Other
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Los Angeles, California • Sacramento, California • Indianapolis, Indiana + 1 more

Conditions: Parkinson Disease
Interventions: NS 2330; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 47
States / cities: Peoria, Arizona • Tucson, Arizona • Fountain Valley, California + 38 more

Conditions: Postoperative Complications
Interventions: Vancomycin; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Obesity
Interventions: sibutramine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy

Vitamin C Supplement for Lumbar Spine Surgery

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Effect of Asimadoline, a Member of a New Medication Class, on Acute Attacks of Pain in Irritable Bowel Syndrome

A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty

Vaginal Baclofen Suppositories in Chronic Pelvic Pain

Bone Response to Soy Isoflavones in Women

Individualized Response to Vitamin D Treatment Study

Terbinafine Treatment of Axial Spondyloarthropathy

Evaluation of Topical Wound Oxygen (two2) Therapy

A Study of Nitazoxanide in Patients With AIDS and Diarrhea Caused by Cryptosporidium

A Placebo-Controlled, Randomized, Safety and Efficacy Study to Evaluate the Change in Hemoglobin A1c Levels in Type 2 Diabetic Subjects While Taking Nutralin

Neuromuscular Intervention Targeted to Mechanisms of ACL Load in Female Athletes

Flax Lignans and Heart Health

Effect of Novel Exhalational Delivery System With Fluticasone (EDS-FLU) on Eustachian Tube Dysfunction (ETD)

A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS 2330 / SCEPTRE)

The Effect of Intrawound Vancomycin Powder on Surgical Site Infection in Inguinal Lymph Node Dissection

Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes